Document Detail


Ximelagatran: pharmacology, pharmacokinetics, and pharmacodynamics.
MedLine Citation:
PMID:  15624336     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Thromboembolism is the largest cause of morbidity and mortality in the western world, yet oral anticoagulation is currently available only with vitamin K antagonists--most often, warfarin. Warfarin has been used for treatment of thrombotic disease for about 50 years. However, despite its widespread use, it is associated with several limitations, such as varied patient response, a narrow therapeutic window, numerous drug and food interactions, and need for frequent therapeutic monitoring. In addition, its full anticoagulant effect usually takes at least 4-5 days after the start of therapy or any dosage change, and it has a slow offset of therapy. A new oral anticoagulant, ximelagatran, has considerable advantages compared with warfarin. The agent requires no therapeutic monitoring, has a wide therapeutic window, and is not known to interact with food or drugs. The advantages ximelagatran brings to clinical practice should be a welcome addition to the options for management of thrombotic disease.
Authors:
Paul P Dobesh
Related Documents :
4093566 - Henry heimlich: a life-saving maneuver for food choking.
18761506 - From lydia pinkham to queen levitra: direct-to-consumer advertising and medicalisation.
8722706 - Hormones and the control of porphyrin biosynthesis and structure in the hamster harderi...
22165856 - Exposure of consumers to morphine from poppy seeds in hungary.
1614946 - Response to angiotensin ii after selective lesioning of brain regions believed to be in...
18547446 - Consumer perceptions of fruit and vegetables serving sizes.
Publication Detail:
Type:  Comparative Study; Journal Article; Review    
Journal Detail:
Title:  Pharmacotherapy     Volume:  24     ISSN:  0277-0008     ISO Abbreviation:  Pharmacotherapy     Publication Date:  2004 Oct 
Date Detail:
Created Date:  2004-12-30     Completed Date:  2005-05-19     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8111305     Medline TA:  Pharmacotherapy     Country:  United States    
Other Details:
Languages:  eng     Pagination:  169S-178S     Citation Subset:  IM    
Affiliation:
Division of Pharmacy Practice, St Louis College of Pharmacy, St Louis, Missouri 63110, USA. pdobesh@stlcop.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Animals
Azetidines / pharmacokinetics*,  pharmacology*,  therapeutic use
Benzylamines
Clinical Trials, Phase III as Topic
Cross-Over Studies
Humans
Meta-Analysis as Topic
Chemical
Reg. No./Substance:
0/Azetidines; 0/Benzylamines; 0/ximelagatran

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Activation of macrophages from lymphoma-bearing mice by liposome mediated intraperitoneal IL-2 and I...
Next Document:  The role of oral direct thrombin inhibitors in the prophylaxis of venous thromboembolism.